Beyond TKIs: Synthetic Lethal Approaches and Targeted Therapies to Watch in Lung Cancer
Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.
Related Articles
Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma
Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.
Artificial Intelligence in Cancer Care and Clinical Trials
Arturo Loaiza-Bonilla, MD, discusses artificial intelligence in cancer care and clinical trials.
Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma
The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.
Cancer Statistics for 2025 – Oncology Nurse Advisor
More than 2 million new cases of cancer will be diagnosed in the US this year, and more than 600,000 people will die of cancer,…
Early Palliative Care Improves EOL Comfort in Colorectal Cancer
Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.
OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025
Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.
Direct Oral Anticoagulants in Extended Treatment of Venous… : Oncology Times
An abstract is unavailable.
‘Call to action’: Head and neck cancer trials in US becoming less diverse
Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past…
8 pictures to help you determine if a breast lump is cause for concern
Lumps and bumps are often early signs of breast cancer. These pictures of breast cancer bumps show you what to look for to determine if…
CAR T-cell Therapy for B-ALL
A panelist discusses how CAR-T cell therapy patient selection involves evaluating disease characteristics like relapse/refractory status and tumor burden, patient-specific factors including performance status and…